Loading...
The antihypertensive drug aliskiren should not be coadministered with angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) in patients with diabetes because doing so may raise risks for renal impairment, hypotension, and hyperkalemia, the FDA announced Friday. The labels of all aliskiren-containing medications will be updated to note this contraindication.
In addition, the new labels will warn against using aliskiren with ACE inhibitors or ARBs in patients with moderate-to-severe renal impairment.
These changes follow preliminary results from the placebo-controlled ALTITUDE trial, in which coadministration of the drugs was associated with increased risks for renal impairment, hypotension, and hyperkalemia. Data also suggest "a slight excess of cardiovascular events" with aliskiren, according to the FDA.
The following brand-name drugs contain aliskiren:
Amturnide
Tekturna
Tekturna HCT
Tekamlo
Valturna
Comment
LINK(S):
FDA MedWatch safety alert (Free)
Previous Physician's First Watch coverage of ALTITUDE (Free)